News

Proteome Sciences is pleased to announce that the Company has completed the next milestone towards the launch of Single Cell Proteomics services, which will be known as SysQuant^® SCP, with the installation of a cellenONE^® (Cellenion, France) platform that allows the semi-automated preparation of up to 2,700 cells per week. 

Thermo Fisher Scientific Recognizes Tandem Mass Tag Grant Award Winner

The directors of Proteome Sciences announce that the Company’s registered office address has changed to Coveham House, Downside Bridge Road, Cobham, Surrey KT11 3EP with immediate effect.

The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 12.00 p.m. today, all resolutions were duly passed.

Annual General Meeting (AGM) Statement

Proteome Sciences is pleased to announce that the Company has secured a contract from a major US academic group. 

The Company has received notification from Vulpes Investment Management Pte Ltd ("Vulpes") that on 22 April 2022 it purchased 183,812 ordinary shares of 1p in the capital of the Company ("Ordinary Shares") at a price of 4p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 67,475,006 Ordinary Shares, equivalent to 22.86% of Proteome Sciences' total issued share capital.

The Company has received notification from Vulpes Investment Management Pte Ltd ("Vulpes") that on 19 April 2022 it purchased 1,465,000 ordinary shares of 1p in the capital of the Company ("Ordinary Shares") at a price of 4p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 67,291,194 Ordinary Shares, equivalent to 22.80% of Proteome Sciences' total issued share capital.

Proteome Sciences plc is pleased to announce that Chief Executive Officer, Dr Mariola Soehngen, will provide a live presentation relating to the Company’s results for the year ended 31 December 2021 via the Investor Meet Company platform on 28 April 2021 at 10.30am BST.